Astria Therapeutics Inc
ATXS6.835USD
+0.275+4.19%
交易中 （美東）報價延遲15分鐘
385.73M總市值
虧損本益比TTM
關於 Astria Therapeutics Inc 公司
Astria Therapeutics, Inc. 是一家專注於開發過敏和免疫疾病療法的生物製藥公司。該公司的領先項目 STAR-0215 是一種單克隆抗體血漿激肽釋放酶抑制劑，目前正在臨牀開發中，用於治療遺傳性血管性水腫 (HAE)，這是一種罕見、使人衰弱且可能危及生命的疾病。其第二個項目 STAR-0310 是一種單克隆抗體 OX40 拮抗劑，目前正在臨牀前開發中，用於治療特應性皮炎 (AD)。該公司擁有兩個針對 STAR-0215 的專利家族。第一個專利家族針對其候選產品 STAR-0215 的物質組成及其在治療包括 HAE 在內的各種血漿激肽釋放酶相關疾病中的用途。在第二個專利系列中，該公司擁有一項國際（PCT）專利申請，針對使用 STAR-0215 抗體的特定給藥方案治療各種血漿激肽釋放酶相關疾病（包括 HAE）的方法。
公司簡介
公司代碼ATXS
公司名稱Astria Therapeutics Inc
上市日期Jun 25, 2015
CEODr. Jill C. Milne, Ph.D.
員工數量78
證券類型Ordinary Share
年結日Jun 25
公司地址22 Boston Wharf Road
城市BOSTON
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編02210
電話16173491971
網址https://astriatx.com/
公司代碼ATXS
上市日期Jun 25, 2015
CEODr. Jill C. Milne, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Jonathan Violin, Ph.D.
Dr. Jonathan Violin, Ph.D.
Independent Director
Independent Director
263.32K
--
Mr. Noah Clauser
Mr. Noah Clauser
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Elizabeth Higgins
Ms. Elizabeth Higgins
Investor Relations
Investor Relations
--
--
Dr. Joanne T. Beck, Ph.D.
Dr. Joanne T. Beck, Ph.D.
Independent Director
Independent Director
--
--
Dr. Jill C. Milne, Ph.D.
Dr. Jill C. Milne, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
--
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
Mr. Andrew Komjathy
Mr. Andrew Komjathy
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Sunil Agarwal, M.D.
Dr. Sunil Agarwal, M.D.
Independent Director
Independent Director
--
--
Mr. Benjamin Scott Harshbarger
Mr. Benjamin Scott Harshbarger
Chief Legal Officer
Chief Legal Officer
--
--
Ms. Andrea Matthews
Ms. Andrea Matthews
Chief Business Officer
Chief Business Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Jonathan Violin, Ph.D.
Dr. Jonathan Violin, Ph.D.
Independent Director
Independent Director
263.32K
--
Mr. Noah Clauser
Mr. Noah Clauser
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Elizabeth Higgins
Ms. Elizabeth Higgins
Investor Relations
Investor Relations
--
--
Dr. Joanne T. Beck, Ph.D.
Dr. Joanne T. Beck, Ph.D.
Independent Director
Independent Director
--
--
Dr. Jill C. Milne, Ph.D.
Dr. Jill C. Milne, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
--
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月16日 週五
更新時間: 5月16日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Perceptive Advisors LLC
11.49%
RA Capital Management, LP
9.05%
Fidelity Management & Research Company LLC
8.52%
Vestal Point Capital, LP
7.41%
Forbion Capital Partners
6.77%
Other
56.77%
持股股東
持股股東
佔比
Perceptive Advisors LLC
11.49%
RA Capital Management, LP
9.05%
Fidelity Management & Research Company LLC
8.52%
Vestal Point Capital, LP
7.41%
Forbion Capital Partners
6.77%
Other
56.77%
股東類型
持股股東
佔比
Investment Advisor
32.69%
Venture Capital
23.81%
Hedge Fund
19.93%
Investment Advisor/Hedge Fund
16.86%
Private Equity
11.49%
Research Firm
1.00%
Individual Investor
0.49%
Pension Fund
0.21%
Bank and Trust
0.19%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
263
60.20M
106.68%
-10.73M
2025Q1
281
59.08M
104.77%
-12.46M
2024Q4
268
59.35M
105.17%
-9.44M
2024Q3
247
57.14M
101.27%
-10.09M
2024Q2
228
56.25M
102.41%
-8.30M
2024Q1
210
58.30M
106.65%
+7.30M
2023Q4
179
37.20M
102.69%
+9.26M
2023Q3
171
23.97M
88.11%
-4.33M
2023Q2
175
25.83M
94.82%
-888.95K
2023Q1
166
24.59M
91.65%
-670.60K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Perceptive Advisors LLC
6.49M
11.49%
--
--
Mar 31, 2025
RA Capital Management, LP
5.11M
9.05%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
4.81M
8.52%
-846.00K
-14.97%
Mar 31, 2025
Vestal Point Capital, LP
4.18M
7.41%
--
--
Mar 31, 2025
Forbion Capital Partners
3.82M
6.77%
+950.00K
+33.07%
Mar 31, 2025
Fairmount Funds Management LLC
3.55M
6.3%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.40M
6.03%
-66.23K
-1.91%
Mar 31, 2025
Millennium Management LLC
2.94M
5.21%
+1.30M
+79.78%
Jun 13, 2025
TCG Crossover Management, LLC
2.76M
4.89%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
2.64M
4.68%
-29.10K
-1.09%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.86%
ALPS Medical Breakthroughs ETF
0.2%
iShares Micro-Cap ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
iShares Biotechnology ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
Avantis US Small Cap Equity ETF
0.02%
iShares Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.86%
ALPS Medical Breakthroughs ETF
佔比0.2%
iShares Micro-Cap ETF
佔比0.05%
ProShares Ultra Nasdaq Biotechnology
佔比0.03%
Invesco Nasdaq Biotechnology ETF
佔比0.03%
iShares Biotechnology ETF
佔比0.02%
iShares Russell 2000 Value ETF
佔比0.02%
Avantis US Small Cap Equity ETF
佔比0.02%
iShares Russell 2000 ETF
佔比0.01%
ProShares Hedge Replication ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Aug 19, 2021
Merger
6<1
Aug 19, 2021
Merger
6<1
Aug 19, 2021
Merger
6<1
Aug 19, 2021
Merger
6<1
公告日期
類型
比率
Aug 19, 2021
Merger
6<1
Aug 19, 2021
Merger
6<1
Aug 19, 2021
Merger
6<1
Aug 19, 2021
Merger
6<1
